ES2216630T3 - Metodos de tratar la hipertension dependiente de la sal. - Google Patents

Metodos de tratar la hipertension dependiente de la sal.

Info

Publication number
ES2216630T3
ES2216630T3 ES99968631T ES99968631T ES2216630T3 ES 2216630 T3 ES2216630 T3 ES 2216630T3 ES 99968631 T ES99968631 T ES 99968631T ES 99968631 T ES99968631 T ES 99968631T ES 2216630 T3 ES2216630 T3 ES 2216630T3
Authority
ES
Spain
Prior art keywords
salt
methods
dependent hypertension
treating
treating dependent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99968631T
Other languages
English (en)
Inventor
George F Schreiner
Richard J Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Scios LLC
Original Assignee
University of Washington
Scios LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Scios LLC filed Critical University of Washington
Application granted granted Critical
Publication of ES2216630T3 publication Critical patent/ES2216630T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Uso del factor de crecimiento vascular endotelial (VEGF) o un agonista del mismo en una cantidad eficaz para reducir la presión sanguínea a un intervalo normal, en la fabricación de un medicamento para el tratamiento de la hipertensión dependiente de la sal.
ES99968631T 1998-09-09 1999-09-09 Metodos de tratar la hipertension dependiente de la sal. Expired - Lifetime ES2216630T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9969498P 1998-09-09 1998-09-09
US12640699P 1999-03-26 1999-03-26
US12661599P 1999-03-27 1999-03-27

Publications (1)

Publication Number Publication Date
ES2216630T3 true ES2216630T3 (es) 2004-10-16

Family

ID=27378887

Family Applications (2)

Application Number Title Priority Date Filing Date
ES99968631T Expired - Lifetime ES2216630T3 (es) 1998-09-09 1999-09-09 Metodos de tratar la hipertension dependiente de la sal.
ES99946776T Expired - Lifetime ES2211165T3 (es) 1998-09-09 1999-09-09 Uso de un factor angiogenico para el tratamiento de angiopatias microvasculares.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES99946776T Expired - Lifetime ES2211165T3 (es) 1998-09-09 1999-09-09 Uso de un factor angiogenico para el tratamiento de angiopatias microvasculares.

Country Status (13)

Country Link
US (3) US6352975B1 (es)
EP (2) EP1112083B1 (es)
JP (2) JP2002524421A (es)
AT (2) ATE260675T1 (es)
AU (2) AU5910599A (es)
BR (2) BR9913533A (es)
CA (2) CA2340320C (es)
DE (2) DE69915310T2 (es)
DK (2) DK1109571T3 (es)
ES (2) ES2216630T3 (es)
IL (2) IL141687A0 (es)
PT (2) PT1112083E (es)
WO (2) WO2000013703A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2216630T3 (es) * 1998-09-09 2004-10-16 Scios Inc Metodos de tratar la hipertension dependiente de la sal.
US6783954B2 (en) * 1999-03-05 2004-08-31 Compugen Ltd. VEGF nucleic acid and amino acid sequences
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
WO2001032695A2 (en) * 1999-11-02 2001-05-10 Genentech, Inc. MODULATION OF eNOS ACTIVITY AND THERAPEUTIC USES THEREOF
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
EP1414964B1 (en) 2001-08-01 2010-03-24 University Of Bristol Vegf isoform
CA2459647A1 (en) * 2001-08-20 2003-02-27 University Of Virginia Patent Foundation Use of s-nitrosothiol signaling to treat disordered control of breathing
US7981863B2 (en) * 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
US20030171556A1 (en) * 2001-12-13 2003-09-11 Chi-Bom Chae Beta-amyloid binding factors and inhibitors thereof
US7795213B2 (en) 2001-12-13 2010-09-14 Posco Methods of contacting β amyloid protein with VEGF
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
JP2006068401A (ja) * 2004-09-03 2006-03-16 Kyushu Institute Of Technology 人工血管
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
MX2007012766A (es) * 2005-04-12 2008-10-01 Intradigm Corp Composición y métodos de terapéuticos de arni para el tratamiento de cáncer y otras enfermedades de neovascularización.
JP5158779B2 (ja) * 2005-08-31 2013-03-06 国立大学法人 香川大学 Ｄ−アロースを有効成分とする血圧上昇抑制剤
MX2011005912A (es) 2008-12-04 2011-06-17 Opko Curna Llc Tratamiento de enfermedades relacionadas con factor de crecimiento endotelial vascular por inhibicion de transcrito antisentido natural para factor de crecimiento endotelial vascular.
GB0921525D0 (en) * 2009-12-08 2010-01-27 Isis Innovation Product and method
AU2018244776B2 (en) 2017-03-30 2023-12-14 Wake Forest University Health Sciences Methods of treatment for kidney disease
CN113418940B (zh) * 2021-06-24 2023-03-14 电子科技大学 一种基于x射线示踪颗粒的检测方法及检测装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456550A (en) 1982-11-22 1984-06-26 President And Fellows Of Harvard College Vascular permeability factor
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
WO1990011084A1 (en) 1989-03-24 1990-10-04 The Regents Of The University Of California Endothelial cell growth factor, isolation and expression
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5219739A (en) 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5240714A (en) * 1989-08-29 1993-08-31 Rof Jose M S Non-digoxin-like Na+, K+ -ATPase inhibitory factor
US5318957A (en) * 1992-09-02 1994-06-07 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating angiogenesis
PT941116E (pt) * 1996-11-01 2005-05-31 Ark Therapeutics Ltd Utilizacao de vegf para o fabrico de um medicamento para o tratamento ou prevencao de hiperplasia da intima e dispositivo de entrega
US6485942B1 (en) * 1997-02-14 2002-11-26 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
ES2216630T3 (es) * 1998-09-09 2004-10-16 Scios Inc Metodos de tratar la hipertension dependiente de la sal.

Also Published As

Publication number Publication date
WO2000013703A9 (en) 2000-06-02
EP1112083B1 (en) 2003-11-12
DE69915310T2 (de) 2005-03-10
DE69915310D1 (de) 2004-04-08
IL141686A0 (en) 2002-03-10
PT1112083E (pt) 2004-03-31
CA2340728A1 (en) 2000-03-16
AU5910599A (en) 2000-03-27
WO2000013703A2 (en) 2000-03-16
CA2340320C (en) 2006-11-14
EP1109571A2 (en) 2001-06-27
AU6028599A (en) 2000-03-27
ES2211165T3 (es) 2004-07-01
JP2002532382A (ja) 2002-10-02
PT1109571E (pt) 2004-05-31
US6352975B1 (en) 2002-03-05
US20040224885A1 (en) 2004-11-11
DE69912815D1 (de) 2003-12-18
ATE260675T1 (de) 2004-03-15
US20020193288A1 (en) 2002-12-19
WO2000013702A3 (en) 2000-09-08
EP1109571B1 (en) 2004-03-03
DK1112083T3 (da) 2004-03-08
JP2002524421A (ja) 2002-08-06
BR9913533A (pt) 2001-06-05
CA2340728C (en) 2007-11-27
DE69912815T2 (de) 2004-10-21
IL141687A0 (en) 2002-03-10
DK1109571T3 (da) 2004-06-21
CA2340320A1 (en) 2000-03-16
ATE253934T1 (de) 2003-11-15
WO2000013702A9 (en) 2000-10-19
WO2000013702A2 (en) 2000-03-16
WO2000013703A3 (en) 2000-07-06
EP1112083A2 (en) 2001-07-04
BR9913564A (pt) 2001-05-22

Similar Documents

Publication Publication Date Title
CL2008003939A1 (es) Uso de escitalopram o una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento de ansiedad social (divisional de la solicitud 1799-00).
ES2166111T3 (es) Uso de tiagabina para el tratamiento de trastornos del sueño.
AR039511A1 (es) Agentes que regulan, inhiben, o modulan la actividad y/o la expresion del factor de crecimiento del tejido conjuntivo (ctgf) como unico medio para disminuir la presion intraocular y para tratar las retinopatias glaucomatosas/neuropatias opticas
AR045179A1 (es) Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer
DE122009000036I1 (de) Verwendung von Dapoxetin, A selektiver Serotonin Aufnahme Inhibitor mit schnellem Wirkungseintritt, zur Behandlung von sexueller Disfunktion
DE69937562D1 (de) Verbessertes angereichertes blutplättchen wundheilmittel
EP1072273A4 (en) VASKULARISIERUNGSINHIBITOREN
ES2250416T3 (es) Estimulante de secreciohn de hormona de crecimiento.
TR200102977T2 (tr) Yeni tedavi yöntemi.
EE200000685A (et) a1 ß1-integriiniretseptori inhibiitorite ja TGF-ß1 inhibiitorite kasutamine neeruhaiguse ravis
DE60143078D1 (de) Pax2 zur behandlung von nierenkrankheiten
AR032422A1 (es) Uso de inhibidores de il-18 para el tratamiento y/o prevencion de la enfermedad cardiaca
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
ATE460938T1 (de) Morpholin-derivate zur verwendung als dopaminagonisten in der behandlung von u.a. sexueller dysfunktion
IT1317930B1 (it) Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione
DE50111407D1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
FR2839450B1 (fr) Preparation medicamenteuse notamment pour le traitement des hernies discales
EA200401454A1 (ru) Новая комбинация из обратимо действующих ингибиторов протонного насоса и используемых в терапии дыхательных путей лекарственных веществ, предназначенных для лечения респираторных заболеваний
RU2002135306A (ru) Способ лечения гнойных ран
DE60135675D1 (de) Behandlung von motorischen veränderungen mit 5-hydrxoytryptamin 1a rezeptor aktivität verstärkenden wirkstoffen
IS5231A (is) Vefjaþáttur sem hefur áhrif á blóðæðarmyndun
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
ATE392213T1 (de) Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen
AR014196A1 (es) Utilizacion del factor de crecimiento igf-i en la fabricacion de composiciones utiles en el tratamiento de la ataxia cerebelar
DE60306344D1 (de) Behandlung von typ i diabetes mellitus mit wachstumshormonantagonisten